Features and Prognosis of Severe Malaria Caused by Plasmodium falciparum, Plasmodium vivax and Mixed Plasmodium Species in Papua New Guinean Children by Manning, Laurens et al.
Features and Prognosis of Severe Malaria Caused by
Plasmodium falciparum, Plasmodium vivax and Mixed
Plasmodium Species in Papua New Guinean Children
Laurens Manning
1, Moses Laman
1,2, Irwin Law
2¤a, Cathy Bona
2, Susan Aipit
2, David Teine
2, Jonathan
Warrell
2, Anna Rosanas-Urgell
2, Enmoore Lin
2, Benson Kiniboro
2, John Vince
3, Ilomo Hwaiwhanje
4,
Harin Karunajeewa
1¤b, Pascal Michon
2¤c, Peter Siba
2, Ivo Mueller
2¤d¤e., Timothy M. E. Davis
1*
.
1School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia, 2Papua New Guinea Institute of
Medical Research, Madang, Madang Province, Papua New Guinea, 3School of Medicine and Health Sciences, University of Papua New Guinea, Boroko, Port Moresby,
Papua New Guinea, 4Department of Pediatrics, Goroka Base Hospital, Goroka, Eastern Highlands Province, Papua New Guinea
Abstract
Background: Mortality from severe pediatric falciparum malaria appears low in Oceania but Plasmodium vivax is increasingly
recognized as a cause of complications and death. The features and prognosis of mixed Plasmodium species infections are
poorly characterized. Detailed prospective studies that include accurate malaria diagnosis and detection of co-morbidities
are lacking.
Methods and Findings: We followed 340 Papua New Guinean (PNG) children with PCR-confirmed severe malaria (77.1% P.
falciparum, 7.9% P. vivax, 14.7% P. falciparum/vivax) hospitalized over a 3-year period. Bacterial cultures were performed to
identify co-incident sepsis. Clinical management was under national guidelines. Of 262 children with severe falciparum
malaria, 30.9%, 24.8% and 23.2% had impaired consciousness, severe anemia, and metabolic acidosis/hyperlactatemia,
respectively. Two (0.8%) presented with hypoglycemia, seven (2.7%) were discharged with neurologic impairment, and one
child died (0.4%). The 27 severe vivax malaria cases presented with similar phenotypic features to the falciparum malaria
cases but respiratory distress was five times more common (P=0.001); one child died (3.7%). The 50 children with P.
falciparum/vivax infections shared phenotypic features of mono-species infections, but were more likely to present in deep
coma and had the highest mortality (8.0%; P=0.003 vs falciparum malaria). Overall, bacterial cultures were positive in only
two non-fatal cases. 83.6% of the children had alpha-thalassemia trait and seven with coma/impaired consciousness had
South Asian ovalocytosis (SAO).
Conclusions: The low mortality from severe falciparum malaria in PNG children may reflect protective genetic factors other
than alpha-thalassemia trait/SAO, good nutrition, and/or infrequent co-incident sepsis. Severe vivax malaria had similar
features but severe P. falciparum/vivax infections were associated with the most severe phenotype and worst prognosis.
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Introduction
The features and prognosis of severe pediatric falciparum
malaria have been characterized in observational and intervention
studies from sub-Saharan Africa [1–4]. Equivalent studies in other
epidemiologic contexts are fewer but important differences have
emerged. There is some evidence that mortality from severe
Plasmodium falciparum infections in children is relatively low in the
Oceania region [5–7], perhaps due to the acquisition of cross-
species functional immunity from greater exposure to P. vivax in
early childhood. Nevertheless, P. vivax is itself increasingly
recognized as a cause of both complications similar to those seen
in falciparum malaria and death [8]. In the case of mixed
Plasmodium species infections (commonly P. falciparum/vivax), there
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29203are reports of reduced [9,10], equivalent [11,12] and increased
[12] morbidity relative to P. falciparum mono-infections.
The incidence of complications and death from severe malaria
will depend on selection/recruitment strategies, sensitivity of
malaria diagnosis/speciation, definitions of severity, inpatient
management including identification of co-incident disease, and
social, cultural and genetic factors that can influence presentation
and clinical course. Apparent inconsistencies between published
studies may reflect differences in one or more such factors. The
characteristics and outcome of severe malaria are, therefore, best
assessed prospectively, in a representative, ethnically homogeneous
sample, and with clinical and laboratory data sufficient both to
allow accurate diagnosis [13] and the detection of important co-
morbidities such as sepsis [14].
We have carried out such a study in children in coastal Papua
New Guinea (PNG) presenting with severe malarial illness, a
setting in which a high prevalence of alpha-thalassemia and South
Asian ovalocytosis (SAO) implies that malaria has had a strong
selective effect [15–17]. We hypothesized that i) severe falciparum
malaria has a low mortality relative to African studies as found
previously in simple observational studies [5–7,18], and that ii)
severe P. vivax and mixed P. falciparum/vivax malaria, although less
common than that caused by P. falciparum, have a similar spectrum
of clinical disease and prognosis.
Methods
Study sites and local malaria epidemiology
The present study was conducted in Madang and Sepik
Provinces on the northern PNG coast where most of the
population are subsistence farmers and their families. The annual
entomological inoculation rate (EIR) for Madang Province has
recently been estimated at 37 for P. falciparum and 24 for P. vivax
[19]. At the Sepik study site, the EIR is 35 for P. falciparum and 12
for P. vivax [20]. In healthy, asymptomatic Madang children aged
1–10 years, the spleen rate is 13% and the prevalence of
parasitemia by microscopy is 8.2% for P. falciparum (median
[interquartile range (IQR)] 1360 [453–2881]/mL) and 14.1% (348
[226–727]/mL) for P. vivax [21]. Approximately 90% of local
children have alpha-thalassemia trait [15]. The national human
immunodeficiency virus (HIV) seroprevalence is 0.9% [22].
Ethics statement
The present study was approved by the PNG Institute of
Medical Research Institutional Review Board and the Medical
Research Advisory Committee of the PNG Health Department,
and conducted according to the principles of the Declaration of
Helsinki. Written informed consent was obtained from parent(s)/
guardian(s) before recruitment.
Patients
Between October 2006 and December 2009, all children aged
0.5–10 years admitted to Modilon Hospital, the provincial hospital
to which the majority of children with severe illness are referred,
were assessed for recruitment to an observational study of severe
pediatric illness. Inclusion criteria included any of: i) impaired
consciousness/coma (Blantyre Coma Score (BCS),5 [23]), ii)
prostration (inability to sit/stand unaided), iii) multiple seizures, iv)
hyperlactatemia (blood lactate.5 mmol/L), v) severe anemia
(hemoglobin,50 g/L), vi) dark urine, vii) hypoglycemia (blood
glucose#2.2 mmol/L), viii) jaundice, ix) respiratory distress, x)
persistent vomiting, xi) abnormal bleeding or xii) signs of shock.
These criteria reflect the World Health Organization (WHO)
definition of severe malarial illness [13]. All severely-ill blood slide-
positive children were considered for recruitment but only those in
whom Plasmodium species were detected by nested polymerase
chain reaction (nPCR) were included in the present analyses. The
final speciation as a mono- or mixed infection was based on the
nPCR result.
Clinical assessment and management
After recruitment, a standardized case report form that
recorded demographic and medical data was completed [24].
This included details of immunizations, past medical history and
recent treatment with antimalarial drugs and antibiotics, as
documented in each child’s hand-held medical record book.
Trained study nurses carried out clinical assessments on admission
and an additional detailed neurological examination was per-
formed by study clinicians (LM, ML) on all children admitted with
a BCS#4, regardless of the time of admission. Weekly bedside
teaching by the study clinicians was conducted to ensure
consistency of clinical assessment by study nurses.
A BCS#2 was considered deep coma and a BCS#4a s
impaired consciousness at 0.5, 1 or 6 hours after correction of
hypoglycemia, a seizure or parenteral anticonvulsant therapy,
respectively. Respiratory distress was considered present if the
child had i) deep breathing, ii) inter-costal in-drawing, iii) sub-
costal recession, iv) persistent alar flaring, v) tracheal tug, and/or
vi) respiratory rate.60/minute. Due to variable availability and
safety concerns, chest radiography was performed in a minority of
children with respiratory symptoms. Inpatient management,
including the decision to perform lumbar puncture (LP), was co-
ordinated by attending ward clinicians under PNG national
guidelines [25] and included intravenous dextrose/saline and
antibiotics (chloramphenicol 25 mg/kg by intramuscular injection
6-hourly), intramuscular artemether (3.2 mg/kg on admission and
1.6 mg/kg daily until oral antimalarial therapy could be tolerated),
and blood transfusion if required (in the absence of cardiovascular
compromise, at a hemoglobin,40 g/L). Each child was reviewed
at least daily until discharge/death. At discharge and, where
possible, at the child’s home two months post-discharge, the
presence of residual neurologic deficits was assessed.
Laboratory Procedures
A baseline venous blood sample was taken for microscopy and
rapid diagnostic testing (RDT) (ICT Diagnostics, Brookvale,
Australia). Giemsa-stained thick blood smears were examined
and the parasitemia quantified independently by two skilled
microscopists with discrepancies adjudicated by a third microsco-
pist [26]. Parasite densities were calculated from the number of
parasites per 200 white cells and an assumed total peripheral white
cell count of 8,000/mL. The final density was the geometric mean
of the two values [26]. Additional on-site tests comprised whole
blood glucose (Hemocue, A ¨ngelholm, Sweden) and lactate
(Lactate Pro, Arkray, Japan), and a full blood count (Coulter
Ac?T diff, Beckman Coulter, Brea, USA).
When sufficient blood was available from the admission
venepuncture after the above tests, 1–3 mL was placed in
Bactec
TM Peds Plus
TM/F bottles (Becton Dickinson, Franklin,
USA) and incubated using an automated Bactec
TM system.
Cerebrospinal fluid (CSF) obtained at LP was examined
macroscopically and microscopically [24], and semi-quantitative
glucose and protein concentrations obtained by urine dipstick
(AconH Laboratories, San Diego, USA) [27]. If.10 white blood
cells/mm
3 were present, CSF was incubated on chocolate agar for
3 days. Bacterial isolates from blood/CSF cultures were identified
using standard procedures [24]. Coagulase-negative staphylococci,
Corynebacterium and Bacillus spp. were considered contaminants. The
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separated plasma and erythrocytes stored at 270uC and 220uC,
respectively.
Additional laboratory tests not necessary for initial clinical
management were performed subsequently and included i) plasma
electrolytes, urea, creatinine, alanine aminotransferase (ALT), total
bilirubin, C-reactive protein (CRP) and creatine kinase (COBAS
INTEGRA 800, Roche Diagnostics, Mannheim, Germany), ii)
Plasmodium speciation by nPCR [28] after parasite DNA extraction
(QIAamp 96 DNA Blood Mini Kit, QIAGEN, Valencia, CA) and
iii) genetic testing for alpha-thalassemia (3.7 kb and 4.2 kb
deletions) and SAO (SLC4A1D27) mutations after host DNA
extraction [29,30]. Serologic testing for HIV was not routinely
performed.
Reference intervals for laboratory tests were determined from
327 healthy Melanesian children who were age- and sex-matched
to the present children [21]. Metabolic acidosis was defined as a
plasma bicarbonate,12.2 mmol/L, hyperbilirubinemia as a
plasma bilirubin.35 mmol/L, an acute inflammatory response
as a plasma CRP.64 mg/L (twice the upper limit of the reference
interval), and significant liver inflammation as a plasma
ALT.90 IU/mL. Schwartz’s formula was used to estimate
creatinine clearance (CrCl) [31], with impaired renal function
defined as a CrCl,75 mL/min.
Prospective population-based study
To compare the proportions of the present hospitalized cases by
Plasmodium species with those of community-acquired malaria in a
similar epidemiologic situation, we used data from 264 children
aged 1–4 years from the Ilaita area of neighbouring East Sepik
Province who were followed with fortnightly active morbidity
assessment and passive case detection at a local health center
between April 2006 and August 2007 [32]. At each visit, an RDT
was performed to guide treatment, and blood slides and
erythrocytes were retained for diagnostic confirmation by
microscopy and PCR, respectively. When a child presented with
severe illness, a detailed adverse event report was completed. A
consensus determination of incident cases of WHO-defined severe
malaria [13] was performed by study clinicians (LM, TMED). The
denominator for severe malaria incidence was the total at-risk
exposure, regardless of antimalarial therapy.
Data analysis
Summary data are presented as median and [IQR]. Compar-
isons of variables between groups were by parametric or non-
parametric tests as appropriate, with post hoc two-group compar-
isons by Dunn’s test for continuous and Bonferroni’s correction for
categorical variables. Crude odds ratios (ORs) for the observed
frequencies of overlapping clinical phenotypes were calculated
using 262 contingency tables. Multivariate analysis was performed
using backward stepwise logistic regression. Variables other than
age were entered based on biological plausibility and P,0.20 on
univariate regression analysis and the most parsimonious model
chosen using Aikake’s Information Criterion. A two-tailed
significance level of P,0.05 was used throughout.
Results
During the study, 3,019 of 3,181(94.9%) hospitalized children
aged between 6 months and 10 years were screened for inclusion
to the study (see Figure 1). Of 353 with presumptive severe malaria
based on microscopy, 13 were excluded because Plasmodium DNA
was undetectable by nPCR. The remaining 340 children had a
median age of 40 [29–55] months and 189 (55.6%) were males. In
most cases (87.1%), both parents were from Madang or East Sepik
provinces, with the rest from other parts of PNG. Based on clinical
features, blood film microscopy and nPCR, there were 262
severely-ill children with P. falciparum (77.1%), 27 with P. vivax
(7.9%), 50 with mixed P. falciparum/vivax (14.7%) and one with
mixed P. falciparum/malariae (0.3%; see Table 1).
Of the sample of 340 children, 19.5%, 5.3% and 5.3%,
respectively, had been treated with oral, parenteral or oral plus
parenteral antimalarial therapy before admission. Prior treatment
was associated with a lower parasite density in children with P.
falciparum mono-infections (median [IQR] 13,347 [1,784-80,560]
vs 68,860 [11,197-171,929] in untreated children, P,0.001) but
not in children with P. vivax mono-infections. For P. falciparum
mono-infections by nPCR, there was 98.5% concordance with
microscopy; two cases were diagnosed as P. vivax and two as P.
falciparum/vivax. For P. vivax mono-infections by nPCR, there was
88.9% concordance with microscopy; three cases were diagnosed
as P. falciparum mono-infections. Six of these seven discordant
results were in patients with low parasite densities (,220/mL). For
mixed P. falciparum/vivax infections, concordance was only 16%,
with 68% diagnosed as P. falciparum and 16% as P. vivax mono-
infections by microscopy.
Presenting features
Of 262 children with severe P. falciparum mono-infections, 81
(30.9%), 65 (24.8%) and 61 (23.2%) had impaired consciousness,
severe anemia, and metabolic acidosis/hyper-lactatemia, respec-
tively (see Figure 2). There were fewer children with the overlap
syndrome of impaired consciousness and severe anemia than
expected by chance alone (OR and 95% confidence intervals (CI)
0.37 (0.18–0.75), P=0.005) and a greater than expected frequency
of impaired consciousness plus acidosis (OR 2.1 (1.1–3.7),
P=0.02). Severe anemia plus acidosis occurred at expected
frequency (OR 1.2 (0.6–1.9), P=0.61). There were 7 children
with all three phenotypes. Only two had hypoglycemia on
admission.
Eight children with severe vivax malaria (29.6%) presented with
impaired consciousness or deep coma, three (11.1%) with severe
anemia, and five (18.5%) with metabolic acidosis or hyperlacta-
temia. Children with severe vivax malaria had higher median
hemoglobin concentrations, smaller spleens, higher median
plasma sodium concentrations, and lower median plasma bilirubin
and CRP concentrations than children with severe falciparum
malaria (see Table 1). After adjustment for the binary variables
hyperlactatemia and severe anemia, the proportion of children
with respiratory distress was five times that in the severe
falciparum malaria group (odds ratio [95% confidence interval]
5.04 [1.84–13.2], P=0.001). There were no other statistically
significant differences between the presenting features of severe
malaria caused by P. vivax or P. falciparum.
When compared to those with severe falciparum malaria,
children with P. falciparum/vivax had a higher median respiratory
rate (P=0.014), a lower BCS (P=0.018) and a greater proportion
with deep coma (P=0.030; see Table 1). In parallel with the severe
P. falciparum cases, these children had lower median hemoglobin
and serum sodium concentrations, and a higher median plasma
bilirubin, than the severe vivax malaria cases. The 5 year-old child
with P. falciparum/malariae presented with fever, abdominal pain
and features of nephrotic syndrome secondary to chronic P.
malariae infection.
Clinical course
Most children responded to antimalarial/supportive therapy
and were discharged well, including the two hypoglycemic
Severe Malaria in PNG Children
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cultures were performed in 258 (75.9%) with contaminants
identified in 13 (5.0%). Only two significant isolates were obtained,
a non-albicans Candida from an admission blood culture from an
immuno-competent child and a Klebsiella pneumoniae from a child
after a week of inpatient treatment for severe malaria. Both
children were treated with appropriate antimicrobial therapy and
discharged well. A LP was performed in 129 children of whom 11
had.10 white blood cells/mL CSF. Routine bacterial culture,
bacterial antigen testing, and India ink staining for Cryptococcus
gattii, were negative in all cases.
Six children (1.8%) died - one with falciparum (0.4%), one with
vivax (3.7%) and four with mixed-species infection (8.0%) - all
within 12 hours of admission. The child with falciparum malaria
presented deeply comatose and died of cardio-respiratory failure.
The fatal P. vivax case was a previously well child who presented
with breathlessness, and abdominal/lower limb swelling. She had
severe respiratory distress, a raised jugular venous pressure and an
oxygen saturation of 92% despite supplementary oxygen. Her
hemoglobin and blood lactate were 41 g/L and 2.7 mmol/L,
respectively. A clinical diagnosis of pericardial effusion with
cardiac tamponade was made and she had a cardio-respiratory
arrest during attempted pericardiocentesis. Subsequent biochem-
ical analysis revealed renal failure (serum creatinine 460 mmol/L),
acidosis and hyperkalemia. The children with mixed P. falciparum/
vivax infections had the greatest mortality (P=0.003 vs falciparum
malaria). Of these four deaths, three were due to cerebral malaria.
The fourth child had a hemoglobin concentration of 19 g/L and
suffered a cardio-respiratory arrest before blood transfusion could
be arranged.
Eight children (2.4%), seven with P. falciparum and one with P.
falciparum/vivax, were discharged with neurologic impairment;
three with deep coma on admission developed cortical blindness
and five had motor deficits ranging from mild ataxia to spastic
quadriparesis. Only two of these eight children had persistent
neurologic deficits at follow-up two months later. Another child
who recovered from severe vivax malaria with respiratory distress
died between discharge and follow-up. When admitted, he had
clinical signs of severe pulmonary hypertension and a prior history
of echocardiographically confirmed cyanotic heart disease.
The genetic deletion causing SAO was present in 17 of 320
(5.3%) children, including 1, 2 and 14 with severe disease due to P.
vivax, mixed P. falciparum/vivax and P. falciparum, respectively.
Three children with SAO deletions presented with deep coma
(BCS of 1, 2 and 2, respectively) and a further four with impaired
consciousness. At least one alpha-thalassemia deletion was
observed in 83.6% of the children with severe malaria (see
Table 1).
Population-based rates of severe malaria
Episodes of malaria during a total of 247 person-years of follow-
up in the East Sepik cohort study [32] are summarized in Table 2.
The data show that the risk of a severe compared with an
uncomplicated P. falciparum/vivax infection is similar to that with P.
falciparum alone (3.4% vs 4.2%, P=0.81 by Fisher’s exact test) but
greater than with P. vivax alone (3.4% vs 0.9%, P=0.035). The
Figure 1. Consort diagram outlining categorization of children presenting to Modilon Hospital, Madang Province, during the study
period. Severe malaria cases were identified by clinical and laboratory features at presentation including blood film microscopy, and subsequent
nPCR for Plasmodium speciation.
doi:10.1371/journal.pone.0029203.g001
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severe anemia (46.7%) and multiple convulsions (36.7%). Two
children with severe falciparum malaria died, one from cardio-
respiratory failure secondary to severe anemia (hemoglobin 16 g/
L). The other was an anemic child (hemoglobin 63 g/L) with P.
falciparum whose condition deteriorated after outpatient antima-
larial treatment and who died 6 hours later.
Discussion
The present study confirms that, although severe P. falciparum
malaria in Melanesian children presents with the same phenotypes
as those in African children, the mortality is low (,1%) in a
hospital setting. The relatively few cases of severe vivax malaria in
our series exhibited presenting features that were similar to those
Table 1. Baseline clinical and laboratory data for children with severe malaria categorized by Plasmodium species.
Plasmodium
falciparum (n=262)
Plasmodium
vivax (n=27)
Plasmodium
falciparum/vivax (n=50) P-value*
Age (months) 42 [30–57] 33 [26–61] 36 [29–48] 0.25
Male sex (%) 58.5 55.6 42.0 0.17
Axillary temperature (uC) 37.9 [37.2–38.7] 37.6 [36.9–38.8] 38.0 [37.0–38.4] 0.28
Pulse rate (/minute) 132 [117–145] 133 [119–146] 139 [121–149] 0.37
Respiratory rate (/minute) 32 [28–38]
a 36 [31.5–43] 38 [31–48] 0.014
Respiratory distress (%) 9.9
b 29.6 22.0 0.002
Oxygen saturation (%) 98 [97–99] 98 [96.5–98.5] 99 [97–100] 0.049
Spleen size (cm) 2 [0–4] 0 [0–2]
c 3 [0–5.3] 0.021
Blantyre Coma Score 5 [4–5]
a 5 [4–5] 4.5 [3–5] 0.018
Impaired consciousness (3–4; %) 20.6 22.2 28.0 ,0.0001
Deep coma (#2; %) 10.3 3.7 22.0
Multiple/complex fits (%) 21.8 25.9 22.0 0.88
Hemoglobin (g/L) 77 [50–94]
b 95 [77–105]
c 73 [50–92] 0.015
Severe anemia (,50 g/L, %) 24.9 11.1 24.0 0.28
Leukocyte count (610
9/L) 8.4 [6.0–12.5] 9 [6.6–12.8] 9.0 [7.1–12.3] 0.67
Platelet count (610
9/L) 101 [56–167] 147 [96.5–204] 127 [71–199] 0.07
Blood lactate (mmol/L) 2.9 [2–4.3] 2.7 [2.0–3.6] 3 [2.1–5.3] 0.63
Hyperlactatemia (.5.0 mmol/L, %) 17.6 7.4 28.0 0.07
Plasma bicarbonate (mmol/L) 16.2 [13.8–18.4] 14.9 [13.7–16.4] 15.1 [13.7–17.4] 0.08
Metabolic acidosis (,12.2 mmol/L, %) 11.6 11.1 16.0 0.68
Blood glucose (mmol/L) 7.6 [6.3–9.1] 7.9 [6–10.5] 7.5 [6.6–9.1] 0.83
Plasma sodium (mmol/L) 129 [127–132]
b 132 [130–134]
c 129 [126–132] 0.007
Plasma creatinine (mmol/L) 26 [21–33] 27 [21–35] 24 [19–32] 0.27
Creatinine clearance (ml/min/1.73 m
2) 166 [140–199] 158 [123–191] 179 [148–212] 0.16
Renal impairment (,75 ml/min/1.73 m
2, %) 3.2 3.7 6.0 0.60
Plasma bilirubin (mmol/L) 11.3 [7.2–22]
b 5.7 [4.1–14]
c 10.0 [6.5–26.5] 0.002
Hyperbilirubinemia (.35 mmol/L, %) 10.5 0.0 14.6 0.13
Plasma C-reactive protein (mg/dL) 99 [51–154]
b 41 [16–81] 72 [23–147] ,0.0001
Plasma C-reactive protein.64 mg/L (%) 70.0
b 37.0 53.2 0.001
Plasma creatine kinase (IU/mL) 67 [17–405] 66 [25–284] 59 [25–592] 0.87
Plasma creatine kinase.2000 IU/mL (%) 9.3 3.8 12.8 0.45
P. falciparum density (parasites/mL) 50061 [4817–130344] 0 [0-0] 18715 [155–126894] 0.07
#
Hyperparasitemia (.100,000/mL, %) 32.1 32.0 1.0
P. vivax density(parasites/mL) 0 [0-0] 1298 [164–4408] 0 [0–107] ,0.0001
South Asian ovalocytosis (SLC4A1D27, %) 5.7 3.8 4.3 0.87
Alpha thalassemia (3.7 or 4.2 kb deletions,
wt/wt, a
del/wt, a
del/a
del,% )
16.2/38.2/45.6 21.7/34.8/43.5 14.6/36.6/48.8 0.95
Data are, unless otherwise stated, median and [inter-quartile range].
aP,0.05 for post-test comparison between P. falciparum vs P. falciparum/vivax;
bP,0.05 for post-test comparison between P. falciparum vs P. vivax;
cP,0.05 for post-test comparison between P. vivax vs P. falciparum/vivax;
*Kruskal-Wallis or Chi-squared test;
#Mann-Whitney test for P. falciparum vs P. falciparum/vivax; wt, wildtype; a
del/wt, heterozygous for either 3.7 or 4.2 kb deletions; a
del/a
del, homozygous or compound
heterozygous for either 3.7 or 4.2 kb deletion.
doi:10.1371/journal.pone.0029203.t001
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likelihood of respiratory distress. Severe mixed P. falciparum/vivax
infections were greater in number than the vivax malaria cases.
These children also had comparable admission clinical/laboratory
findings to those of the patients with severe falciparum and vivax
malaria, but their subsequent mortality was the highest of the three
groups. These observations confirm and extend data relating to
severe malaria in an area of intense transmission of multiple
Plasmodium species, especially in relation to mixed-species infec-
tions.
Our children with severe falciparum malaria had rates of
impaired consciousness, acidosis, anemia, and combinations of
these, that were similar to those reported in African studies [1–
4,33–35]. Impaired consciousness was more often associated with
acidosis than severe anemia, again paralleling African data [1]. We
had two cases of hypoglycemia, a prevalence of 0.8%. In the
recent large-scale African Quinine Artesunate Malaria Trial
(AQUAMAT) [36], 10% of children were hypoglycemic at
recruitment. This suggests that the nutritional status of our
children, including hepatic glycogen reserves (which may reflect
differences in duration and/or severity of illness), was better than
in African children. Alternatively, a proportion of the patients had
received quinine prior to recruitment to AQUAMAT with the risk
of attendant hyperinsulinemia [37]. There may also be genetic
differences in glucose metabolism between African and Melane-
sian populations that account for differences in hypoglycemia risk.
Figure 2. Overlapping clinical phenotypes of severe malaria caused by Plasmodium falciparum.
doi:10.1371/journal.pone.0029203.g002
Table 2. Uncomplicated and severe malaria numbers, and incidence of severe malaria, by infecting Plasmodium species from a
longitudinal surveillance study of 264 children followed over 17 months in neighbouring East Sepik Province.
Plasmodium species Uncomplicated malaria (n) Severe malaria (n) Severe malaria (%)
Incidence of severe malaria per
1,000 person-years at risk
falciparum 483 21 4.2
{ 81.8
vivax 461 4 0.9 16.1
falciparum/vivax 140 5 3.4
{ 20.2
Other* 50 0 0 0
Total 1134 30 2.6 (1.8–3.8)
" 121 (82–173)
"
Data are from Lin et al. [32].
*Single or mixed infections with P. malariae or P. ovale;
"(95% confidence intervals);
{P,0.05 vs P. vivax.
doi:10.1371/journal.pone.0029203.t002
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malaria lie between 3% and 50% [1–4]. Our results are consistent
with other Melanesian studies in showing lower mortality [5,6,18].
This difference could reflect protective genetic factors, relatively
infrequent hypoglycemia and bacteremia, and/or better access to
quality healthcare. We found alpha-thalassemia deletions in
83.6% of our children, a lower percentage than the 97% found
in the general Madang population, and 5.3% had SAO deletions
reflecting the results of previous studies in the province [16,17].
These polymorphisms have previously been shown to be protective
against complications of malaria [15–17,38,39], including near
complete protection for SAO against cerebral malaria [16,38].
Although our study was not designed to assess such a protective
effect, the observation that three children with cerebral malaria
had the SAO deletion, as did a further four children with impaired
consciousness, contrasts with previous studies. This finding
suggests that unrecognized favourable genetic traits other than
SAO and alpha-thalassemia have emerged through strong
selection pressure which might help explain the low mortality
observed in our children.
African studies show hypoglycemia-associated mortality of
.50% [34], but neither of our two hypoglycemic children died.
Similarly, invasive bacterial disease has been detected in 5–8% of
African children with severe malaria, especially non-typhoidal
Salmonellae infection that substantially increase mortality [14], but
there was a much lower rate in our cohort. Most of our children
had blood cultures performed with an acceptable contamination
rate. While we identified invasive bacterial isolates from children
severe non-malarial disease (data not shown), only two significant
pathogens were obtained from our children with severe malaria.
Unregulated antibiotic access is widespread in PNG, but only
8.4% and 7.6%, respectively, had documented amoxicillin or
chloramphenicol treatment before admission suggesting that prior
antibiotic therapy was not responsible. In addition, no Salmonellae
were isolated from the present or other children with severe non-
malarial disease studied contemporaneously (data not shown). All
our children were treated empirically with intramuscular arte-
mether, parenteral chloramphenicol and other supportive therapy
[25], and prompt access to good quality standard treatment may
also have contributed to their relatively low mortality. Neverthe-
less, children in the AQUAMAT study had similar management
but even those treated with artesunate rather than quinine had a
mortality of 8.5% [36].
Severe vivax malaria has been associated with a wide variety of
clinical manifestations in adults and children that include severe
anemia, altered consciousness, respiratory distress, jaundice,
thrombocytopenia, acidosis and renal failure [8,12,40–44]. There
are, however, large between-study differences in the frequency of
individual presenting features. This reflects, in part, the fact that
few studies have involved prospective collection of clinical and
laboratory data sufficient to capture the broad range of features of
severe malaria, exclude other causes of severe illness and confirm
Plasmodium speciation using molecular methods.
A case in point is respiratory distress. In one of two recent
prospective studies of severe pediatric P. vivax infection from the
island of New Guinea [12], children had a limited clinical
assessment that included respiratory rate and oxygen saturation.
These two features were used to define respiratory distress that was
present in approximately 5% of children with severe P. vivax
malaria. In the second study, which involved prospective
community-based morbidity surveillance [41], respiratory distress
defined as a respiratory rate.40–50/minute in the presence of
chest in-drawing or a history of breathlessness was present in
60.5% of 86 children identified with severe vivax malaria over 8
years. Our prevalence of respiratory distress, based on well-defined
specific criteria including a higher respiratory rate threshold, was
intermediate between these two figures. Consistent with the other
PNG study [41] but not the study from southern Papua [12],
respiratory distress was more common in our P. vivax cases than
those with P. falciparum. Acute respiratory distress syndrome
(ARDS), interstitial pneumonia and pulmonary oedema can
complicate vivax malaria in adults [8]. Since P. vivax-infected
erythrocytes can bind to cells expressing endothelial receptors
known to mediate the cytoadhesion of P. falciparum [45], this could
reflect parasite microvascular sequestration [46] which may be
prominent in the pulmonary capillary bed [47]. This phenomenon
may have contributed to respiratory distress in the child with
cyanotic heart disease, but there is also evidence that such children
may be at increased risk of other manifestations of severe malaria
including altered consciousness [48].
There was a single death from P. vivax malaria in our cohort.
Although this child died during attempted pericardiocentesis, she
had severe anemia, respiratory distress, renal impairment and
acidosis. In the larger observational study from southern Papua
[12] that revealed a case fatality rate for severe vivax malaria in
young children (approaching 2%) comparable to that in the
present study (3.7%), these presenting features were strongly
predictive of death. In a retrospective study from north-eastern
Indonesian Papua [11], the overall death rate for severe vivax
malaria was 25% in 36 cases. The mortality from severe infections
(P. falciparum or vivax) was lower in children than adults but no
pediatric-specific vivax malaria mortality data were reported in
this study or a previous prospective observational study from PNG
[41].
Our children with severe mixed P. falciparum/vivax infections had
clinical and laboratory features that were mostly similar to those of
the severe falciparum cases despite generally lower P. falciparum
parasitemias. The exceptions were a higher baseline respiratory
rate and a lower BCS. These features suggest that the children in
this group were the most severely ill, at risk of the pathophysiologic
effects of both parasite species with the possibility that P. vivax
microvascular cytoadherence as observed in lung [47] and spleen
[46] might also occur in the brain.
Other studies have found that, in contrast to the present data,
severe anemia is less common in severe P. falciparum/vivax
infections than severe falciparum or vivax malaria [12], that
mixed infections are more likely than P. vivax infections to be
associated with respiratory distress [41], and that coma is least
likely in mixed infections [41]. These apparent inconsistencies may
reflect between-study differences in patient selection, definitions of
complications, and the availability and quality of clinical/
laboratory data including accurate microscopy and/or molecular
confirmation of Plasmodium species. Nevertheless, our data indicate
that WHO criteria for severe malaria [13] that are based on
studies of P. falciparum encompass the spectrum of severe infections
caused by P. vivax with or without co-incident P. falciparum.
Although from a study with a different design, the community-
based longitudinal data from a cohort of similarly aged East Sepik
children who had similar red-cell polymorphisms and who were
from an area of comparable malaria transmission [32], suggest
that both P. falciparum mono-infections and P. falciparum/vivax
infections in a PNG child are more likely to progress to severe
disease than P. vivax mono-infections. Indeed, the numbers of
severe cases in these categories (21, 5 and 4, respectively) were
consistent those of the present study (262, 50 and 27), suggesting
that our hospitalized patients were representative of malaria in the
community. The mortality in our series was greatest in severe P.
falciparum/vivax infections, consistent with the presenting clinical
Severe Malaria in PNG Children
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with mortality data [11,12], there was no significant difference
between mixed and single-species infections but no pediatric-
specific outcomes were included. Thus, our data are the first to
suggest that mixed-species infections carry an adverse prognosis in
children.
Our study had limitations. It is possible that the most severely ill
children in the study catchment area die before they can be
transferred for inpatient care, thus compromising the representa-
tive nature of our sample. Due mainly to issues with obtaining a
sufficient volume of blood from a small, distressed and severely ill
child, we could not exclude bacteremia in every case, while
diagnostic tests for viral and fungal pathogens were not possible in
this clinical setting. Obtaining post mortem tissue samples that may
have clarified underlying pathology is culturally problematic in
PNG.
The strengths of the present study were its prospective
standardized data collection, the use of nPCR as a way of
compensating for the known limitations of microscopy, and the
availability of bacteriology facilities that enabled detection of
common invasive bacterial infections. Such a rigorous approach
has been used in few previous descriptive studies of severe
childhood malaria. Our data confirm the lack of sensitivity of
microscopy in identifying mixed species infections [49,50], with
low-level P. vivax densities that can be missed by microscopy in this
situation probably reflecting density dependent cross-species
regulation [51]. Although nPCR is not a quantitative test and
the relative contribution of each species to the overall parasitemia
remains uncertain, microscopic misdiagnosis of mixed infections in
previous studies may have obscured the association with more
severe disease observed in the present patients. Given the
presenting features and clinical course of our patients, it is unlikely
that there were significant numbers of cases with diagnoses that
would have been identified by specialized serologic and other tests.
Indeed, in the case of encephalitis, more than one third of cases
remain undiagnosed in a resource-rich healthcare setting [52]. It
has been suggested that parasite density thresholds are employed
in areas where asymptomatic parasitemia is common in otherwise
healthy children [53,54]. While the severe malaria-attributable
fraction or diagnostic specificity increases with higher parasitemia,
sensitivity is reduced. The choice of threshold will depend on
factors such as local transmission, age-dependent malarial
immunity and genetic factors modulating infection severity.
The present study of well-characterized children from an area of
intense transmission of multiple Plasmodium species has identified
significant differences between the presentation and outcome of
severe P. falciparum, vivax and falciparum/vivax infections in PNG.
The low mortality observed for severe falciparum malaria does not
appear related to high endemicity of P. vivax but may reflect
protective genetic factors, better prior nutrition, and/or less
exposure/susceptibility to secondary bacterial infection than in
African children. Severe vivax malaria presents with features seen
in severe P. falciparum infections but respiratory distress is more
prominent, suggesting preferential cytoadherence of this parasite
within the lung microvasculature. Severe P. falciparum/vivax
infections in PNG children appear to have the worst prognosis,
perhaps because they share the adverse presenting features of the
respective mono-infections. These findings provide impetus for
further research on the pathogenic potential of P. vivax infections
when this parasite is present alone and especially in combination
with other Plasmodium species.
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